A cost-consequence analysis of the preferential use of secukinumab versus adalimumab for the treatment of psoriatic arthritis Alberto Jiménez-Morales; Rafael Cáliz; Susana Aceituno; Miriam Prades; Carles Blanch;

Psoriasis induced by biological therapy Lydia Montolio Chiva; Àngels Martínez Ferrer; Almudena Mateu Puchades; Cristina Campos Fernández; Javier Narváez Garcia; Juan José Alegre Sancho;

Paradoxical reaction after switching between adalimumab biosimilars in a patient with psoriatic arthritis Mariano F. Palatnik; Emilce S. Fonseca; María Lorena Brance;